• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Addition of docetaxel to first-line long-term hormone therapy in prostate cancer (STAMPEDE): modelling to estimate long-term survival, quality-adjusted survival, and cost-effectiveness

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    main.pdf
    Size:
    846.0Kb
    Format:
    PDF
    Description:
    Full text, Open Access article
    Download
    Authors
    Woods, BS
    Sideris, E
    Sydes, MR
    Gannon, MR
    Parmar, MKB
    Alzouebi, M
    Attard, G
    Birtle, AJ
    Brock, S
    Cathomas, R
    Chakraborti, PR
    Cook, A
    Cross, WR
    Dearnaley, D
    Gale, J
    Gibbs, S
    Graham, JD
    Hughes, R
    Jones, RJ
    Laing, R
    Mason, MD
    Matheson, D
    McLaren, DB
    Millman, R
    O'Sullivan, JM
    Parikh, O
    Parker, CC
    Peedell, C
    Protheroe, A
    Ritchie, AWS
    Robinson, A
    Russell, JM
    Simms, MS
    Srihari, NN
    Srinivasan, R
    Staffurth, JN
    Sundar, S
    Thalmann, GN
    Tolan, S
    Tran, Anna T
    Tsang, D
    Wagstaff, J
    James, ND
    Sculpher, MJ
    Show allShow less
    Affiliation
    Centre for Health Economics, University of York, York, UK.
    Issue Date
    2019
    
    Metadata
    Show full item record
    Citation
    Woods BS, Sideris E, Sydes MR, Gannon MR, Parmar MKB, Alzouebi M, et al. Addition of docetaxel to first-line long-term hormone therapy in prostate cancer (STAMPEDE): modelling to estimate long-term survival, quality-adjusted survival, and cost-effectiveness. Eur Urol Oncol. 2018 Dec;1(6):449-58.
    Journal
    European Urology Oncology
    URI
    http://hdl.handle.net/10541/621949
    DOI
    10.1016/j.euo.2018.06.004
    PubMed ID
    31158087
    Additional Links
    https://dx.doi.org/10.1016/j.euo.2018.06.004
    Type
    Article
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1016/j.euo.2018.06.004
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
    • Authors: James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, Ritchie AW, Parker CC, Russell JM, Attard G, de Bono J, Cross W, Jones RJ, Thalmann G, Amos C, Matheson D, Millman R, Alzouebi M, Beesley S, Birtle AJ, Brock S, Cathomas R, Chakraborti P, Chowdhury S, Cook A, Elliott T, Gale J, Gibbs S, Graham JD, Hetherington J, Hughes R, Laing R, McKinna F, McLaren DB, O'Sullivan JM, Parikh O, Peedell C, Protheroe A, Robinson AJ, Srihari N, Srinivasan R, Staffurth J, Sundar S, Tolan S, Tsang D, Wagstaff J, Parmar MK, STAMPEDE investigators
    • Issue date: 2016 Mar 19
    • A Cost-effectiveness Analysis of Systemic Therapy for Metastatic Hormone-sensitive Prostate Cancer.
    • Authors: Sathianathen NJ, Alarid-Escudero F, Kuntz KM, Lawrentschuk N, Bolton DM, Murphy DG, Kim SP, Konety BR
    • Issue date: 2019 Nov
    • Addition of docetaxel and/or zoledronic acid to standard of care for hormone-naive prostate cancer: a cost-effectiveness analysis.
    • Authors: Zhang P, Wen F, Fu P, Yang Y, Li Q
    • Issue date: 2017 Jul 31
    • Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data.
    • Authors: Clarke CS, Hunter RM, Gabrio A, Brawley CD, Ingleby FC, Dearnaley DP, Matheson D, Attard G, Rush HL, Jones RJ, Cross W, Parker C, Russell JM, Millman R, Gillessen S, Malik Z, Lester JF, Wylie J, Clarke NW, Parmar MKB, Sydes MR, James ND
    • Issue date: 2022
    • Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol.
    • Authors: Sydes MR, Spears MR, Mason MD, Clarke NW, Dearnaley DP, de Bono JS, Attard G, Chowdhury S, Cross W, Gillessen S, Malik ZI, Jones R, Parker CC, Ritchie AWS, Russell JM, Millman R, Matheson D, Amos C, Gilson C, Birtle A, Brock S, Capaldi L, Chakraborti P, Choudhury A, Evans L, Ford D, Gale J, Gibbs S, Gilbert DC, Hughes R, McLaren D, Lester JF, Nikapota A, O'Sullivan J, Parikh O, Peedell C, Protheroe A, Rudman SM, Shaffer R, Sheehan D, Simms M, Srihari N, Strebel R, Sundar S, Tolan S, Tsang D, Varughese M, Wagstaff J, Parmar MKB, James ND, STAMPEDE Investigators
    • Issue date: 2018 May 1
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.